ReviewPathologie (Heidelberg, Germany)2026
[Cutaneous clear cell sarcoma].
Review in Pathologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClear cell sarcoma is a rare, aggressive neoplasm with melanocytic differentiation, characterised by an EWSR1 fusion with ATF1, CREB1 or CREM. In addition to the classic deep-seated variant, a significantly rarer dermal/cutaneous form exists. First described in 2009, it is frequently misdiagnosed due to its histopathological and immunohistochemical overlap with melanoma.
objectiveThis review aims to summarise the current state of knowledge on cutaneous clear cell sarcoma, including pathogenesis, histopathology, immunohistochemistry, molecular pathology and differential diagnoses, to raise awareness of this underdiagnosed entity. MATERIAL AND
methodsA comprehensive literature search was conducted in PubMed/MEDLINE without time restrictions, focusing on clear cell sarcomas (specifically cutaneous cases) and CRTC1::TRIM11 cutaneous tumours. All English-language publications deemed relevant were evaluated regarding clinical, histopathological, immunohistochemical and molecular genetic features.
resultsApproximately 55 cases of cutaneous clear cell sarcoma have been published to date; they are thus significantly rarer than classic deep-seated cases. They show a broader anatomical distribution, a smaller size, and a somewhat less aggressive course than the latter. They predominantly affect young adults with a female predominance. Histologically, they consist of fascicles and nests of epithelioid and spindled cells with melanocytic marker expression. PRAME is the only helpful immunohistochemical marker in the distinction from melanoma. The main differential diagnosis, besides melanoma, is the CRTC1::TRIM11 cutaneous tumour, which, based on current evidence, has a more favourable prognosis. DISCUSSION: Molecular confirmation of the EWSR1 rearrangement is desirable for diagnosis, as the differentiation from other neoplasms, including melanoma and CRTC1::TRIM11 cutaneous tumours, has important therapeutic and prognostic consequences.
Indexed as
Identifiers
42307723What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.